Non-alcoholic fatty liver disease (NAFLD), and its progression to non-alcoholic steatohepatitis (NASH), is estimated to become the most common chronic liver condition in Western populations. However, the etiology of NAFLD/NASH is not well understood, and, despite many Phase III trials, a drug has not yet been approved for treatment. Therefore, ongoing research is essential. Clinical medical imaging can be an effective tool to appropriately confirm patient eligibility and monitor treatment efficacy in NAFLD/NASH drug development. Further, independent central review and analyses of medical images can ensure high-quality results throughout the duration of the trial.
Download our case study to learn how advanced medical imaging played an important role during the clinical trial conducted by Viking Therapeutics to evaluate VK2809 for the treatment of patients with biopsy-proven NASH with fibrosis.